Show simple item record

dc.contributor.authorPatel, PH
dc.contributor.authorPalma, D
dc.contributor.authorMcDonald, F
dc.contributor.authorTree, AC
dc.date.accessioned2019-06-24T08:56:32Z
dc.date.issued2019-12
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2019, 31 (12), pp. 824 - 833
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3270
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2019.05.015
dc.description.abstractOligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease. In the era of well-tolerated targeted treatments, resistance inevitably occurs and overcoming this is a challenge. Local ablative therapy for oligoprogressive disease may allow the continuation of systemic treatments by overcoming the few sub-clones that have developed resistance. Stereotactic body radiotherapy is now frequently used in treating oligometastatic disease using ablative doses with minimally invasive techniques and acceptable toxicity. We discuss the current retrospective clinical evidence base supporting the use of local ablative therapy for oligoprogression in metastatic patients on targeted treatments within multiple tumour sites. As there is currently a lack of published prospective data available, the best management for these patients remains unclear. We discuss current trials in recruitment and the potential advancements in treating this group of patients with stereotactic radiotherapy.
dc.formatPrint-Electronic
dc.format.extent824 - 833
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectDisease Progression
dc.subjectRadiosurgery
dc.subjectRetrospective Studies
dc.subjectProspective Studies
dc.titleThe Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
dc.typeJournal Article
dcterms.dateAccepted2019-04-17
rioxxterms.versionofrecord10.1016/j.clon.2019.05.015
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2019-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume31
pubs.embargo.termsNot known
dc.contributor.icrauthorTree, Alisonen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0